A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the activity of TPI 287 as single agent
therapy for patients with advanced, unresectable pancreatic cancer after failure of
gemcitabine-containing therapy. Activity of TPI 287 will be determined by the 6-month
survival rate.